ArticleArthritis & rheumatology (Hoboken, N.J.)2025
Recurrence Risk in Pediatric Noninfectious Uveitis During Adalimumab Tapering: An International Multicenter Retrospective Study.
Article in Arthritis & rheumatology (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Advances in tumor necrosis factor-α inhibitors for the treatment of juvenile idiopathic arthritis-associated uveitis.Frontiers in immunology · 2026Review
- Dose Exploration Based on Quantitative Pharmacokinetic Analysis of Monoclonal Antibodies for Pediatric Immune-Mediated Diseases: Current Evidence and Future Directions.Drug design, development and therapy · 2026Review
- Clinical characteristics, management, and outcomes of pediatric non-infectious uveitis: A multicenter study in Saudi Arabia.PloS one · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aims to assess the risk of noninfectious uveitis (NIU) relapse in pediatric patients undergoing adalimumab (ADA) tapering, evaluating potential predictors of such risk.
methodsWe conducted a multicenter retrospective cohort study involving pediatric patients with NIU who underwent ADA tapering due to inactive uveitis. Cox proportional hazards regression was used to analyze risk factors for NIU recurrence.
resultsThe study cohort comprised 114 patients (65 girls; 57%). Most commonly, patients presented with juvenile idiopathic arthritis-associated uveitis (JIA-U) (52 of 114; 46%) or idiopathic uveitis (46 of 114; 40%). At ADA tapering, 46% of patients (53 of 114) experienced NIU recurrence after an overall median time of 30 weeks (interquartile range [IQR] 15-58 weeks) from the start of ADA tapering. Patients without recurrences were observed for a median of 70 weeks (IQR 48-98 weeks). Multivariate Cox regression analysis showed that a slower ADA tapering schedule was associated with a lower recurrence rate during the waning (hazard ratio [HR] 0.40, 95% confidence interval [CI] 0.21-0.74; P < 0.01). Subgroup analysis of patients with JIA-U indicated that beginning ADA tapering after at least two years of disease inactivity significantly reduced recurrence risk (HR 0.65, 95% CI 0.43-0.95; P = 0.05). Among 59 patients (52%) who discontinued ADA, recurrence rates were similar between fast- and slow-tapering groups (21% vs 33%; P = 0.6), but median time to recurrence was shorter with fast tapering (10 weeks vs 37 weeks; P = 0.05).
conclusionThis study highlights the significant clinical impact of ADA tapering on uveitis recurrence risk, recommending a gradual, slow-tapering approach with close monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.